New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
15:35 EDTCELGCelgene reports positive results from PALACE-1 study of psoriatic arthritis
The company previously announced statistical significance for the primary endpoint of ACR20 for patients receiving apremilast in the PALACE-1 study, the first of three pivotal phase III, randomized, placebo-controlled studies evaluating the company's novel, oral small-molecule inhibitor of phosphodiesterase 4 in patients with psoriatic arthritis who had received oral disease-modifying antirheumatic drugs and/or biologic therapy and/or had failed on an anti-tumor necrosis factor agent. Apremilast treatment in this study was used alone or in combination with oral DMARDs. PALACE-1 is the first phase III study demonstrating statistical significance in a psoriatic arthritis patient population that included both prior biologic exposure (23.6%) and biologic failures (9.3%). In the study, apremilast demonstrated statistically significant and higher ACR20 responses at week 16 in patients receiving either apremilast 20 or 30 mg BID monotherapy (31.5% and 50.8% respectively vs. 10.5% for placebo; P<0.05 and P<=0.0001), with no meaningful advantage to adding oral DMARDs to apremilast. A higher ACR20 response at week 16 was also demonstrated in biologic-naive subjects receiving apremilast 30 mg BID monotherapy compared with placebo (59% vs. 12%; P<0.005).
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use